Vitamin K1 Injection (Phytonadione Injectable Emulsion, USP) is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity.
Market Analysis and Insights: Global Vitamin K1 Injection Market
Due to the COVID-19 pandemic, the global Vitamin K1 Injection market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 2mg/mL accounting for % of the Vitamin K1 Injection global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Vitamin K1 Injection market size is valued at US$ million in 2021, while the US and Europe Vitamin K1 Injection are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Vitamin K1 Injection landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Vitamin K1 Injection include AdvaCare, Innopharma, Suicheng Pharmaceutical, Cheng Yi Pharmaceutical, Wuhu Kangqi Pharmaceuticals, Jiangsu Huayang Pharmaceutical and Brilliant Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Vitamin K1 Injection Scope and Segment
Vitamin K1 Injection market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Vitamin K1 Injection market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
2mg/mL
5mg/mL
10mg/mL
Segment by Application
Hospital
Clinic
Others
By Company
AdvaCare
Innopharma
Suicheng Pharmaceutical
Cheng Yi Pharmaceutical
Wuhu Kangqi Pharmaceuticals
Jiangsu Huayang Pharmaceutical
Brilliant Pharmaceutical
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE